Michael McCormack
Pulmonary Disease · Knoxville, TNNPI 1114934676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,219 and has fallen 97.8% since, to $27 in 2023. That places this record below the midpoint for pulmonary disease clinicians in TN, where the typical reported total is $3,628.
Across 159 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$415
- AstraZeneca$336
- Boehringer Ingelheim$327
- Insmed, Inc.$283
- Actelion Pharmaceuticals US, Inc.$263
- United Therapeutics Corporation$202
- plus $851 from 15 others
What the payments were for
- Food & beverage$2,60297%
- Education$753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $415 |
| AstraZeneca(2 entities) | 12 | $336 |
| Boehringer Ingelheim | 18 | $327 |
| Insmed, Inc. | 18 | $283 |
| Actelion Pharmaceuticals US, Inc. | 18 | $263 |
| United Therapeutics Corporation | 10 | $202 |
| Grifols USA, LLC | 11 | $186 |
| Genentech USA, Inc. | 9 | $137 |
| AbbVie | 8 | $130 |
| Merck | 5 | $89 |
| Cook Medical LLC | 3 | $82 |
| Inogen, Inc. | 2 | $56 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Electromed, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $21 |
| Vapotherm Inc | 1 | $20 |
| Olympus America Inc. | 1 | $19 |
| Gilead | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Pfizer | 1 | $11 |
How this compares
$2,677 in reported general payments places this provider in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ColistimethateColistin (Colistimethate Na) | 11 | $1,180 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Knoxville
- John SwisherKnoxville$234K
- John PrinceKnoxville$117K
- Rajiv DhandKnoxville$96K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Shannon ByrdKnoxville$23K
- James PharaohKnoxville$20K
- Isaac BineyKnoxville$16K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.